NCT03834272View on ClinicalTrials.gov

Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions
Peritoneal Metastases
Interventions
COMBINATION_PRODUCT

LUM Imaging System

Patients will be injected with one of 3 study doses of LUM015 and tissue will be imaged in vivo with the LUM imaging device. Some patients may be imaged with an additional imaging device.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Lumicell, Inc.
All Listed Sponsors
lead

Lumicell, Inc.

INDUSTRY